These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 31810606

  • 1. Long non-coding RNA SSTR5-AS1 facilitates gemcitabine resistance via stabilizing NONO in gallbladder carcinoma.
    Xue Z, Yang B, Xu Q, Zhu X, Qin G.
    Biochem Biophys Res Commun; 2020 Feb 19; 522(4):952-959. PubMed ID: 31810606
    [Abstract] [Full Text] [Related]

  • 2. LncRNA DYNLRB2-AS1 promotes gemcitabine resistance of nasopharyngeal carcinoma by inhibiting the ubiquitination degradation of DHX9 protein.
    Chen KL, Huang SW, Yao JJ, He SW, Gong S, Tan XR, Liang YL, Li JY, Huang SY, Li YQ, Zhao Y, Qiao H, Xu S, Zang S, Ma J, Liu N.
    Drug Resist Updat; 2024 Sep 19; 76():101111. PubMed ID: 38908233
    [Abstract] [Full Text] [Related]

  • 3. Overexpression of LncRNA AFAP1-AS1 predicts poor prognosis and promotes cells proliferation and invasion in gallbladder cancer.
    Ma F, Wang SH, Cai Q, Zhang MD, Yang Y, Ding J.
    Biomed Pharmacother; 2016 Dec 19; 84():1249-1255. PubMed ID: 27810781
    [Abstract] [Full Text] [Related]

  • 4. Overexpression of microRNA-205-5p exerts suppressive effects on stem cell drug resistance in gallbladder cancer by down-regulating PRKCE.
    Zhang GF, Wu JC, Wang HY, Jiang WD, Qiu L.
    Biosci Rep; 2020 Sep 30; 40(9):. PubMed ID: 32869841
    [Abstract] [Full Text] [Related]

  • 5. Long non-coding SBF2-AS1 acting as a competing endogenous RNA to sponge microRNA-142-3p to participate in gemcitabine resistance in pancreatic cancer via upregulating TWF1.
    Hua YQ, Zhu YD, Xie GQ, Zhang K, Sheng J, Zhu ZF, Ning ZY, Chen H, Chen Z, Meng ZQ, Liu LM.
    Aging (Albany NY); 2019 Nov 04; 11(20):8860-8878. PubMed ID: 31619579
    [Abstract] [Full Text] [Related]

  • 6. LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway.
    Xu F, Huang M, Chen Q, Niu Y, Hu Y, Hu P, Chen D, He C, Huang K, Zeng Z, Tang J, Wang F, Zhao Y, Wang C, Zhao G.
    Cancer Res; 2021 Nov 15; 81(22):5678-5691. PubMed ID: 34593522
    [Abstract] [Full Text] [Related]

  • 7. Long noncoding RNA FOXD2-AS1 accelerates the gemcitabine-resistance of bladder cancer by sponging miR-143.
    An Q, Zhou L, Xu N.
    Biomed Pharmacother; 2018 Jul 15; 103():415-420. PubMed ID: 29674277
    [Abstract] [Full Text] [Related]

  • 8. LncRNA-HGBC stabilized by HuR promotes gallbladder cancer progression by regulating miR-502-3p/SET/AKT axis.
    Hu YP, Jin YP, Wu XS, Yang Y, Li YS, Li HF, Xiang SS, Song XL, Jiang L, Zhang YJ, Huang W, Chen SL, Liu FT, Chen C, Zhu Q, Chen HZ, Shao R, Liu YB.
    Mol Cancer; 2019 Nov 21; 18(1):167. PubMed ID: 31752906
    [Abstract] [Full Text] [Related]

  • 9. Histone acetyltransferase 1 promotes gemcitabine resistance by regulating the PVT1/EZH2 complex in pancreatic cancer.
    Sun Y, Ren D, Zhou Y, Shen J, Wu H, Jin X.
    Cell Death Dis; 2021 Sep 25; 12(10):878. PubMed ID: 34564701
    [Abstract] [Full Text] [Related]

  • 10. M6A RNA Methylation-Mediated Dysregulation of AGAP2-AS1 Promotes Trastuzumab Resistance of Breast Cancer.
    Cai Y, Zheng H, Xu D, Xie J, Wang W, Liu Z, Zheng Z.
    Pharmacology; 2024 Sep 25; 109(5):282-292. PubMed ID: 38744264
    [Abstract] [Full Text] [Related]

  • 11. miR-218-5p restores sensitivity to gemcitabine through PRKCE/MDR1 axis in gallbladder cancer.
    Wang H, Zhan M, Xu SW, Chen W, Long MM, Shi YH, Liu Q, Mohan M, Wang J.
    Cell Death Dis; 2017 May 11; 8(5):e2770. PubMed ID: 28492560
    [Abstract] [Full Text] [Related]

  • 12. Long non-coding RNA LINC-PINT attenuates paclitaxel resistance in triple-negative breast cancer cells via targeting the RNA-binding protein NONO.
    Chen J, Zhu M, Zou L, Xia J, Huang J, Deng Q, Xu R.
    Acta Biochim Biophys Sin (Shanghai); 2020 Aug 05; 52(8):801-809. PubMed ID: 32632453
    [Abstract] [Full Text] [Related]

  • 13. Maslinic acid potentiates the antitumor activities of gemcitabine in vitro and in vivo by inhibiting NF-κB-mediated survival signaling pathways in human gallbladder cancer cells.
    Yu Y, Wang J, Xia N, Li B, Jiang X.
    Oncol Rep; 2015 Apr 05; 33(4):1683-90. PubMed ID: 25633045
    [Abstract] [Full Text] [Related]

  • 14. LncRNA MNX1-AS1 sustains inactivation of Hippo pathway through a positive feedback loop with USP16/IGF2BP3 axis in gallbladder cancer.
    Liu S, Li H, Zhu Y, Ma X, Shao Z, Yang Z, Cai C, Wu Z, Li M, Gong W, Wu X.
    Cancer Lett; 2022 Oct 28; 547():215862. PubMed ID: 35953000
    [Abstract] [Full Text] [Related]

  • 15. ELF3 promotes gemcitabine resistance through PKMYT1/CDK1 signaling pathway in gallbladder cancer.
    Yang L, Wang H, Guo M, He M, Zhang W, Zhan M, Liu Y.
    Cell Oncol (Dordr); 2023 Aug 28; 46(4):1085-1095. PubMed ID: 36988891
    [Abstract] [Full Text] [Related]

  • 16. LncRNA AGAP2-AS1 augments cell viability and mobility, and confers gemcitabine resistance by inhibiting miR-497 in colorectal cancer.
    Hong S, Yan Z, Song Y, Bi M, Li S.
    Aging (Albany NY); 2020 Mar 23; 12(6):5183-5194. PubMed ID: 32202509
    [Abstract] [Full Text] [Related]

  • 17. YTHDF2 promotes gallbladder cancer progression and gemcitabine resistance via m6A-dependent DAPK3 degradation.
    Bai X, Chen J, Zhang W, Zhou S, Dong L, Huang J, He X.
    Cancer Sci; 2023 Nov 23; 114(11):4299-4313. PubMed ID: 37700438
    [Abstract] [Full Text] [Related]

  • 18. PLAC8 overexpression correlates with PD-L1 upregulation and acquired resistance to chemotherapies in gallbladder carcinoma.
    Gong K, Gong ZJ, Lu PX, Ni XL, Shen S, Liu H, Wang JW, Zhang DX, Liu HB, Suo T.
    Biochem Biophys Res Commun; 2019 Aug 27; 516(3):983-990. PubMed ID: 31272718
    [Abstract] [Full Text] [Related]

  • 19. LncRNA TTN-AS1 acts as a tumor promoter in gallbladder carcinoma by regulating miR-107/HMGA1 axis.
    Lin Z, Li Y, Shao R, Hu Y, Gao H.
    World J Surg Oncol; 2021 Jun 05; 19(1):163. PubMed ID: 34090483
    [Abstract] [Full Text] [Related]

  • 20. Epigenetic activation of the elongator complex sensitizes gallbladder cancer to gemcitabine therapy.
    Xu S, Jiang C, Lin R, Wang X, Hu X, Chen W, Chen X, Chen T.
    J Exp Clin Cancer Res; 2021 Nov 25; 40(1):373. PubMed ID: 34823564
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.